Four more business daysuntil the expected closing of the merger.
Interesting timing.
AEZS's diagnostic test trial is expected to be completed in the next month with topline results in Q3. This sets the stage for potential licensing. In a previous deal AEZS received an inflation-adjusted ~C$40 million upfront plus other potential payments and royalties. PGX 5X scale-up was said almost complete last month. Three trial runs had been completed. The 5X scale-up was to provide material for potential partners with the 10X scale-up expected to be completed next quarter. A licensing deal could happen at any time. The 10X PGX scale-up is the decision point for mass industrialization. The avenanthramide single-dose escalation study should be near completion setting the stage for the release of the safety/tolerability results a CZO moves to the two dose portion of the study. CZO has submitted its data for the fibrosis program to the journal Biomaterials. Previously a short toxicology study was said all that was needed. Dr. Martin Kolb said that if preclinical results were replicated in humans it could profoundly alter the teatment landscape. Last October AEZS anticipated preclinical Harvard data for the NSMOD candidate shortly. It is also expected to seek advice on the regulatory path forward for two programs.
With the key data and deal expected there could be new analyst coverage. H.C. Wainwright's previous target for AEZS was C$100 million market cap and this was a merger of equals.